For instance, a clinical trial involving 46 HCC patients (NCT05032014) is currently recruiting participants to evaluate the impact of the probiotic Lactobacillus rhamnosus Probio‐M9 on the response to PD‐1 inhibitor therapy [98]. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.